

# Pre-clinical study and IND application of PAT101, a tophaceous gout treatment, using SelecAll™ technology



OTHERS	Preclinical
Product Type	Liquid type
Indication	Tophaceous gout
Target	Uric acid
MoA(Mechanism of Action)	This supplied urate oxidase, PAT101, catalyzes the conversion of insoluble uric acid accumulated in joints and other tissues into allantoin, which is then easily excreted through Kidney
Competitiveness	<ul style="list-style-type: none"> <li>• Site-specific conjugation technique minimizes structural modification of protein drugs, enabling maintenance of therapeutics' intrinsic activity while reducing side-effects including immunogenicity through the use of human serum albumin</li> <li>• It is a new alternative that allows re-dosing for patients who have not responded to existing medication (Krystexxa)</li> </ul>
Development Stage	Preclinical
Route of Administration	Intravenous Infusion